Search Page

1

Cite

Share

Emerging drugs for treatment of focal segmental glomerulosclerosis.

Trachtman H. Trachtman H. Expert Opin Emerg Drugs. 2020 Sep;25(3):367-375. doi: 10.1080/14728214.2020.1803276. Epub 2020 Aug 12. Expert Opin Emerg Drugs. 2020. PMID: 32729368 Free PMC article. Review.

Cite

Share

2

Cite

Share

HUS and TTP in Children.

Trachtman H. Trachtman H. Pediatr Clin North Am. 2013 Dec;60(6):1513-26. doi: 10.1016/j.pcl.2013.08.007. Pediatr Clin North Am. 2013. PMID: 24237985 Free PMC article. Review.

Cite

Share

3

Cite

Share

Novel therapies for FSGS: preclinical and clinical studies.

Malaga-Dieguez L, Bouhassira D, Gipson D, Trachtman H. Malaga-Dieguez L, et al. Adv Chronic Kidney Dis. 2015 Mar;22(2):e1-6. doi: 10.1053/j.ackd.2014.10.001. Adv Chronic Kidney Dis. 2015. PMID: 25704355 Free PMC article. Review.

Cite

Share

4

Cite

Share

Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.

Kiffel J, Rahimzada Y, Trachtman H. Kiffel J, et al. Adv Chronic Kidney Dis. 2011 Sep;18(5):332-8. doi: 10.1053/j.ackd.2011.03.005. Adv Chronic Kidney Dis. 2011. PMID: 21896374 Free PMC article. Review.

Cite

Share

5

Cite

Share

Galactose treatment in focal segmental glomerulosclerosis.

Trachtman H, Savin VJ. Trachtman H, et al. Pediatr Nephrol. 2014 May;29(5):931. doi: 10.1007/s00467-013-2700-8. Epub 2013 Dec 22. Pediatr Nephrol. 2014. PMID: 24362723 Free PMC article. No abstract available.

Cite

Share

6

Cite

Share

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS. Ternant D, et al. Eur J Clin Pharmacol. 2016 Feb;72(2):253-5. doi: 10.1007/s00228-015-1973-1. Epub 2015 Oct 31. Eur J Clin Pharmacol. 2016. PMID: 26521258 Clinical Trial. No abstract available.

Cite

Share

7

Cite

Share

Bisphenol A exposure is associated with low-grade urinary albumin excretion in children of the United States.

Trasande L, Attina TM, Trachtman H. Trasande L, et al. Kidney Int. 2013 Apr;83(4):741-8. doi: 10.1038/ki.2012.422. Epub 2013 Jan 9. Kidney Int. 2013. PMID: 23302717 Free PMC article.

Cite

Share

8

Cite

Share

Pediatric chronic kidney disease in North Carolina.

Ferris M, Patel UD, Massengill S, Gipson D, Conley W, Layton JB, Nagaraj S, Primack W. Ferris M, et al. N C Med J. 2008 May-Jun;69(3):208-14. N C Med J. 2008. PMID: 18751354 Free PMC article. No abstract available.

Cite

Share

9

Cite

Share

Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.

Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Roberts BV, et al. J Clin Pharmacol. 2013 Sep;53(9):919-24. doi: 10.1002/jcph.121. Epub 2013 Jun 29. J Clin Pharmacol. 2013. PMID: 23813330 Free article. Clinical Trial.

Cite

Share

10

Cite

Share

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS. Trachtman H, et al. BMC Nephrol. 2015 Jul 22;16:111. doi: 10.1186/s12882-015-0094-5. BMC Nephrol. 2015. PMID: 26198842 Free PMC article. Clinical Trial.

Cite

Share